Figure 2: Representation of the HAE virtual patient population capturing patient variability in the propensity for acute attacks represented by frequency and severity
0%
10%
20%
30%
40%
1 2 3 4 5 6 7 MoreMonthly attack rate
0%5%
10%15%20%25%30%
Dis
trib
utio
n pe
rcen
tage
Dis
trib
utio
n pe
rcen
tage
PKa inhibitor pharmacokineticsvia random sampling
Variability in acute attack triggervia random sampling
1 2 3 4 5 6 1110987 More
Virtual HAE population
Fold increase in FXII auto-activation
Patient1 = (Pt1, f1, S1)Patient2 = (Pt2, f2, S2)Patientn = (Pt1, fn, Sn)
Contact activation system pharmacodynamic model
FXII = factor XII; HAE = hereditary angioedema; PKa = plasma kallikrein.
*Lanadelumab is approved as prophylaxis to prevent attacks of HAE in patients ≥12 years of age in the United States and for the routine prevention of attacks in patients ≥12 years of age in Canada.9,10 Lanadelumab also was approved in the European Union, Australia, and Brazil for the routine prevention of recurrent attacks of HAE in patients ≥12 years of age,11-13 and in Switzerland for the long-term prevention of attacks of HAE in patients ≥12 years of age.14
References: 1. Banerji A, et al. JAMA 2018;320:2108-2121. 2. Aygören-Pürsün E, et al. N Engl J Med 2018;379:352-362. 3. Kalfus I, et al. Presented at the Annual Scientific Session of the Western Society of Allergy, Asthma and Immunology; January 20–4, 2019; Maui, HI. 4. Hampton SL, et al. J Allergy Clin Immunol 2019;143:AB39. 5. van der Graaf PH, Benson N. Pharma Res 2011;28:1460-1464. 6. Nussberger J, et al. Lancet 1998;351:1693-1697. 7. Suffritti C, et al. Clin Exp Allergy 2014;44:1503-1514. 8. Osterberg L, Blaschke T. N Engl J Med 2005;353:487-497. 9. Shire. Highlights of prescribing information. Takhzyro™ (lanadelumab-flyo) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf. Accessed January 6, 2020. 10. Shire Pharma Canada. Product monograph including patient medication information. Takhzyro™ (lanadelumab injection). https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/takhzyro-pm-en.pdf. Accessed January 6, 2020. 11. European Medicines Agency. Takhzyro 300 mg solution for injection. Summary of product characteristics. http://ec.europa.eu/health/documents/community-register/2018/20181122143033/anx_143033_en.pdf. Accessed January 6, 2020. 12. Takhzyro Australian product information. https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia. Accessed January 6, 2020. 13. Takhzyro Brazilian product information. http://portal.anvisa.gov.br/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column 1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=5676578&_101_type=content&_101_groupId=219201&_101_urlTitle =takhzyro-novo-registro&redirect=http%3A%2F%2Fportal.anvisa.gov.br%2Fresultado-de-busca%3Fp_p_id%3D3%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_ mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_3_groupId%3D0%26_3_keywords%3Dlanadelumab%26_3_cur%3D1%26_3_struts_action %3D%252Fsearch%252Fsearch%26_3_format%3D%26_3_formDate%3D1441824476958. Accessed January 6, 2020. 14. Swissmedic. Takhzyro, solution for injection. https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/authorised-medicinal-products-with-new-active-substances/takhzyro_injektionsloesung_lanadelumabum.html. Accessed January 6, 2020.
Funding and acknowledgments: We thank all patients, investigators, and their study staff. This study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company. Under the direction of the authors, Hoa Q. Nguyen, employee of Takeda, provided writing assistance for this poster. Editorial assistance in formatting, proofreading, copyediting, and fact-checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this poster. The interpretation of the data was made by the authors independently.
RationaleRationale ■ Hereditary angioedema (HAE) is a rare inherited disorder characterized by recurrent episodes (also called attacks) of severe swelling of the skin and mucous membranes.
■ Unopposed contact system activation leads to excess plasma kallikrein (PKa) activity and, subsequently, increased bradykinin, a key mediator of HAE attacks.■ PKa inhibitors reduce contact system activation and have been approved or are in development for HAE.■ Lanadelumab, a fully human monoclonal antibody inhibitor of PKa (half-life of ~14 days) approved for HAE prophylaxis in several regions,* reduced attack
rates at 300 mg administered every 2 weeks (q2wks) for 26 weeks by ~87% compared with placebo in the phase 3 HELP Study (NCT02586805).1
■ We sought to understand the impact of target binding kinetics, pharmacokinetics, and treatment adherence on maintaining HAE disease control with lanadelumab versus small molecule PKa inhibitors (half-life of 20 hours) in development for HAE prophylaxis via a quantitative systems pharmacology (QSP) approach.2-5
MethodsMethods■ A mechanistic biological model of HAE was developed using QSP that incorporated critical components of the contact system and a virtual HAE patient
population (Figures 1 and 2).■ Cleaved high molecular weight kininogen pharmacodynamic biomarker data and clinical outcomes from lanadelumab clinical studies were used to verify the
model within an acceptable range (Figures 3–5).■ The verified model was used to evaluate the impact of various drug-related factors on HAE disease outcome, including binding potency, treatment
adherence (assessed via virtual patient populations by QSP modeling), and half-life (Figures 6–9).
ResultsResultsModel development
3 ways to access the poster
Mobile and environmentally friendly e-posters
No personal information is stored - standard charges may apply.
Send an SMS:Text 474396
To 43704 (USA only)+44 7860 033 046 (rest of world)
Access online www.shirecongressposters.com/474396
Scan QR code
Presented at the American Academy of Asthma, Allergy & Immunology Annual Meeting, March 13–16, 2020, Philadelphia, PA
Hereditary Angioedema Prophylaxis With Plasma Kallikrein Inhibitors: Role of Target Hereditary Angioedema Prophylaxis With Plasma Kallikrein Inhibitors: Role of Target Binding Kinetics, Pharmacokinetics, and Treatment AdherenceBinding Kinetics, Pharmacokinetics, and Treatment Adherence
Rangaraj Narayanan,1* Haobin Luo,2 Zhiwei Zhang,2 Paul Jasper,2 Peng Lu,1* Salomé Juethner,1 Dan Sexton1
1Shire, a Takeda company, Cambridge, MA, USA; 2RES Group Inc., Needham, MA, USA*Affiliation at the time the analysis was conducted
327
ConclusionsConclusions■ A QSP model of excess contact system activation coupled with virtual population of patients with HAE was developed to quantitatively
describe the dynamic interactions of the contact factors and PKa inhibitors. The model successfully captures the clinical outcomes oflanadelumab in virtual patients with HAE.
■ The model was applied to investigate the role of target binding and pharmacokinetics and showed that drugs with long half-lives (>2 weeks)had ≥2-fold improved efficacy versus those with short half-lives (20 hours).
■ For small molecules with short half-lives, the model suggested that the more missed doses, the higher the HAE attack occurrence.■ Drug development programs address noncompliance and nonpersistence via the development of drugs that require less frequent dosing
and demonstrate longer half-lives.
Model qualification
Model applicationRole of target binding kinetics and pharmacokinetics Impact of treatment nonadherence in patients
Figure 6: Monthly attack rates for 150 mg QD oral small molecule PKa inhibitors with different Ki values
Ki = 0.30 nM
Ki = 0.50 nM
0
1
2
3
4
5
Week–4
Week0
Week+4
Week+8
Week+12
Week+16
Week+20
Week+24
Week+28
Week+32
Week+36
Att
acks
/mo
nth
First dose Last dose
Ki = inhibition constant; PKa = plasma kallikrein; QD = once-daily.
In the absence of plasma protein binding, for a 150 mg QD dose, the binding affinity needs to be strong enough (eg, <0.3 nM) to effectively suppress attacks.
Figure 8: Example pharmacokinetics of drug X 150 mg QD and bradykinin profiles with a nonadherence rate of 20%
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
1
10
100
1000
0 4 8 12 16 20 24 28
Dru
g X
pla
sma
con
cen
trat
ion
(n
g/m
L)
Week
Drug X Bradykinin
Bra
dyk
inin
(n
M)
HAE = hereditary angioedema; QD = once daily.
Nonadherence for daily dosing of drug X could negatively impact the suppression of HAE attacks because each missed dose would reduce drug coverage and make the patient more prone to HAE attacks.
Figure 7: Efficacy of drugs with shorter half-lives (20 hours)
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14Day
95th percentile Mean 5th percentile
0
20
40
60
80
100
–4 0 4 8 12 16 20 24 28
%H
Ka
Week
95th percentile Mean 5th percentile150 mg QD
0
1
2
3
4
5
6
Week–4
Week0
Week+4
Week+8
Week+12
Week+16
Week+20
Week+24
Week+28
Week+32
Week+36
Att
acks
/mo
nth
Plas
ma
con
cen
trat
ion
Placebo 110 mg 150 mg
First dose Last dose
Predicted %HKaPharmacokinetics of example drug with half-life 20 hours
150 mg QD
Hka = cleaved high molecular weight kininogen; QD = once daily; q2wks = every 2 weeks.
Figure 1: QSP model of in vivo contact system activation
Depot(PKa inhibitor)
FXII FXIIa
Kallikrein
HK +
C1-INH
B1R/B2R
BradykininR P P G F S P F R
Feedbackloop
F, ka
Central(CL, Vc)
Clinical outcome(reduction of HAE
attack rate)
Prekallikrein
Auto-activation
C1-INH
HKa(key biomarker)
C1-INH = C1-inhibitor; CL = clearance; F = fraction of dose absorbed; FXII = factor XII; FXIIa = activated factor XII; HAE = hereditary angioedema; HK = high molecular weight kininogen; HKa = cleaved high molecular weight kininogen; ka = absorption rate constant; PKa = plasma kallikrein; QSP = quantitative systems pharmacology; Vc = central volume of distribution.
Figure 3: QSP model approximated observed %PKa inhibition data from phase 1a (NCT01923207) and phase 1b (NCT02093923) lanadelumab studies
0
20
40
60
80
100
0 20 40 60 80 100 120 140
DataBasal prekallikrein (250 nM)Basal prekallikrein (650 nM)
0
20
40
60
80
100
0 20 40 60 80 100 120 140
DataBasal prekallikrein (250 nM)Basal prekallikrein (650 nM)
–20–10
010203040506070
0 14 28 42 56 70 84 98 112
DosedVehicleBasal prekallikrein (250 nM)Basal prekallikrein (650 nM)
–20
–10
0
10
20
30
40
50
0 14 28 42 56 70 84 98 112Time (days)
DosedVehicleBasal prekallikrein (250 nM)Basal prekallikrein (650 nM)
% in
hib
itio
n o
fPK
a ac
tivi
ty%
inh
ibit
ion
of
PKa
acti
vity
% in
hib
itio
n o
fPK
a ac
tivi
ty%
inh
ibit
ion
of
PKa
acti
vity
3 mg/kg 1 mg/kg
300 mg 400 mg
Time (days)
Time (days) Time (days)
Phase 1a study: healthy volunteers (single dose)
Phase 1b study: patients with HAE (repeated dose)
HAE = hereditary angioedema; PKa = plasma kallikrein; QSP = quantitative systems pharmacology.
Figure 4: QSP model approximated observed %HKa levels from the phase 3 lanadelumab study (NCT02586805)
0
20
40
60
80
100
–8 –4 0 4 8 12 16 20 24 28 32 36 40 44
%H
Ka
Time (weeks)
%HKa for 300 mg q2wks5th percentile 95th percentileMedian Mean
HKa = cleaved high molecular weight kininogen; q2wks = every 2 weeks; QSP = quantitative systems pharmacology.
Median %HKa (57%) modeled in 1000 virtual patients approximately matched previous reports.6
Figure 5: QSP model prediction of monthly HAE attack rates in 1000 virtual patients approximated observed attack rates from the phase 3 lanadelumab study (NCT02586805)
012345
Week –4 Week 0 Week +4 Week +8 Week +12 Week +16 Week +20 Week +24 Week +28
Att
acks
/mo
nth
150 mg q4wks Data Model
012345
Att
acks
/mo
nth
300 mg q4wks
012345
Att
acks
/mo
nth
300 mg q2wks
First dose Last dose
Week –4 Week 0 Week +4 Week +8 Week +12 Week +16 Week +20 Week +24 Week +28
Week –4 Week 0 Week +4 Week +8 Week +12 Week +16 Week +20 Week +24 Week +28
HAE = hereditary angioedema; q2wks = every 2 weeks; q4wks = every 4 weeks; QSP = quantitative systems pharmacology.
Model suggests that drugs with shorter half-lives and weaker binding affinity have higher HKa and attack rates (≥2-fold greater) compared with lanadelumab (half-life of ~14 days) at 300 mg q2wks dosing.
Impact of treatment nonadherence in patients■ Pharmacology adherence rates
to daily oral therapy in thereal-world setting report an 80%mean adherence, with a rangeof ~65–90%.8
■ Nonadherence was studied fordrugs with shorter half-lives(drug X) using populationsimulations with an assumedaverage of occurrence ofnonadherences (random missingdose) of 20% for a virtual patientpopulation (ie, 6 missed doses ina 30-day month).
Figure 9: Simulated numbers of monthly attacks during treatment of drug X 150 mg QD with different nonadherence rates
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Fulladherence
15%missed dose
20%missed dose
30%missed dose
40%missed dose
50%missed dose
Att
acks
/mo
nth
Placebo Drug X 150 mg QD
HAE = hereditary angioedema; QD = once daily.
The monthly attack profiles showed that the more missed doses, the higher the HAE attack occurrence. Simulations showed 6–8 days of randomly missed doses out of 4 weeks daily dosing could translate to a ~2-fold efficacy decline. At ≥50% missed dose scenario, treatment with drug results in marginal efficacy.
%reduction of attack rates compared with placebo
Fulladherence
15%misseddose
20%misseddose
30%misseddose
40%misseddose
50%misseddose
Drug X 150 mg QD
53.9 41.9 35.5 23.9 21.3 13.2
■ Frequency (f): number of attack events fora patient was randomly simulated from Poisondistribution, with an average of 2.2 attacksper month.
■ Severity (S): severity of attack was modeledas an increase in FXII auto-activation. Theincrease of FXII auto-activation (assumednormal distribution) was sampled so that thebradykinin levels during attack are in line withliterature range.6
■ Simulated HAE attacks occurred whenbradykinin levels exceeded a predefinedthreshold plasma concentration in patientswith HAE (20 pM).7
Top Related